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Key messages
 ► In this study, non-physician healthcare personnel 
perform and interpret lung ultrasound (LUS) exam-
inations, facilitating an assessment of the appropri-
ate level of healthcare provider for these tasks.
 ► Serial LUS examinations allow for an assessment of 
how LUS may be used to characterise the progres-
sion of chest indrawing pneumonia in children and 
may help prioritise which children require further 
care.
 ► The study is enrolling in two very different settings 
with very different study populations, which may re-
flect distinct underlying pneumonia epidemiologies 
or potentially lead to difficulties in harmonising the 
data between sites; however, the ability to assess 
LUS in two diverse geographies is also a strength 
of this study.
AbstrAct
Introduction Pneumonia is the leading infectious cause 
of death among children under 5 years of age worldwide. 
However, pneumonia is challenging to diagnose. Lung 
ultrasound (LUS) is a promising diagnostic technology. 
Further evidence is needed to better understand the role of 
LUS as a tool for the diagnosis of childhood pneumonia in 
low-resource settings.
Methods and analysis This study aims to pilot LUS 
in Mozambique and Pakistan and to generate evidence 
regarding the use of LUS as a diagnostic tool for childhood 
pneumonia. Children with cough <14 days with chest 
indrawing (n=230) and without chest indrawing (n=40) 
are enrolled. World Health Organization Integrated 
Management of Childhood Illness assessment is performed 
at enrolment, along with a chest radiograph and LUS 
examination. Respiratory and blood specimens are 
collected for viral and bacterial testing and biomarker 
assessment. Enrolled children are followed for 14 days 
(in person) and 30 days (phone call) post-enrolment 
with LUS examinations performed on Days 2, 6 and 14. 
Qualitative and quantitative data are also collected to 
assess feasibility, usability and acceptability of LUS among 
healthcare providers and caregivers. The primary outcome 
is LUS findings at enrolment with secondary outcomes 
including patient outcomes, repeat LUS findings, viral and 
bacterial test results, and patient status after 14 and 30 
days of follow-up.
Ethics and dissemination This trial was approved by the 
Western Institutional Review Board as well as local ethics 
review committees at each site. We plan to disseminate 
study results in peer-reviewed journals and international 
conferences.
trial registration number NCT03187067.
IntroductIon
Pneumonia is the leading infectious cause of 
childhood mortality worldwide.1 2 In addition 
to preventing pneumonia, there is a critical 
need to provide greater access to appro-
priate diagnostics and effective treatment. 
Childhood pneumonia is challenging to 
diagnose. Currently, in low-resource settings 
(LRS), pneumonia is diagnosed using WHO 
Integrated Management of Childhood Illness 
(IMCI) guidelines that rely on assessing vari-
able and subjective clinical signs like respira-
tory rate and chest indrawing.3 Given the limi-
tations of these non-specific clinical signs, it is 
not fully understood how effective WHO IMCI 
guidelines are in identifying pneumonia.
Diagnostic alternatives to WHO IMCI have 
challenges as well.4 Clinical diagnosis not 
using WHO IMCI guidelines lacks standard-
isation and can lead to empiric antibiotic 
administration. Chest radiography (CXR) 
can be costly, difficult to obtain and time 
consuming and exposes the child to ionising 
radiation.4 5 Microbiology (eg, blood culture, 
lung/pleural aspiration and/or broncho-
alveolar lavage) can be slow, is invasive and 
only detects a limited proportion of cases.4 
Biomarkers such as C reactive protein can 
correlate with bacterial infection but have no 
set threshold and do not indicate a specific 
aetiology.4
Lung ultrasound (LUS) is a promising 
pneumonia diagnostic technology that 
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Figure 1 Map of study areas.16 17
has demonstrated high diagnostic accuracy.5 There is 
compelling evidence that indicates that LUS may have 
greater sensitivity, similar specificity and better interop-
erator reliability when compared with CXR, a diagnostic 
not readily available in LRS.6–10 Additional advantages 
of LUS, relative to CXR, include its portability, ease of 
use, lower cost and absence of ionising radiation.5 11 The 
goal of this pilot is to generate evidence to build a greater 
consensus regarding the use of LUS as a tool for the diag-
nosis of childhood pneumonia in LRS.
MEthods And AnAlysIs
study design and setting
The primary objectives of this prospective, observational, 
facility-based cohort study are: (1) to provide scientific 
evidence assessing whether the addition of LUS to the 
current pneumonia pathways improves identification 
of pneumonia in children 2 through 23 months of age 
presenting to district hospitals in Manhiça, Mozambique 
and Karachi, Pakistan and (2) to determine whether 
LUS is feasible, usable and acceptable among healthcare 
providers (HCPs) and caregivers of children with respira-
tory symptoms for diagnosing and managing pneumonia 
in these settings. This study is conducted at Manhiça 
District Hospital, the referral health facility for the entire 
Manhiça District in Mozambique and at Sindh Govern-
ment Children’s Hospital–Poverty Eradication Initiative, 
a district hospital for the District Central, the largest 
district in Karachi, Pakistan (figure 1).
study participants
Children aged 2 through 23 months presenting to a study 
hospital with a history of cough with a duration of less 
than 14 days and/or difficulty breathing are recruited by 
good clinical practice (GCP)-trained hospital staff during 
routine intake and screening procedures in the hospitals’ 
outpatient and/or emergency departments and referred 
to trained study staff for study screening. To avoid poten-
tial selection bias, referred children are screened for 
enrolment in a sequential manner as much as possible. 
Referred children are considered for enrolment as cases 
if they present with chest indrawing or for enrolment 
as controls if they present with no chest indrawing, fast 
breathing or fever. Trained study staff assess the child 
for all inclusion and exclusion criteria (table 1). Final 
eligibility determination depends on the results of the 
medical history, clinical examination including WHO 
IMCI assessment, appropriate understanding of the study 
and completion of the written informed consent process. 
Cases and controls may be inpatient or outpatient at the 
discretion of the study site.
For the feasibility, usability and acceptability assess-
ment, study HCPs, healthcare administrators and care-
givers at each site are invited to participate. HCPs and 
healthcare administrators are enrolled if they are 18 
years or older, involved in or aware of the study and 
have provided written informed consent. Caregivers are 
enrolled if they are 18 years or older, have a child enrolled 
in the study and are willing to participate in an in-depth 
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Table 1 Study definitions and eligibility criteria
Definitions
Fast breathing for age  ► Children 2 to <12 months of age: RR ≥50 breaths per minute
 ► Children≥12 months of age: RR ≥40 breaths per minute
Severe respiratory distress Grunting, nasal flaring and/or head nodding
WHO IMCI general danger signs Lethargy or unconsciousness, convulsions, vomiting everything, inability to drink or 
breastfeed
Eligibility criteria
Inclusion criteria Cases
 ► 2 through 23 months of age
 ► Cough <14 days or difficulty breathing
 ► Visible indrawing of the chest wall with or without fast breathing for age
 ► Ability and willingness of child’s caregiver to provide informed consent and to be 
available for follow-up for the planned duration of the study, including accepting a home 
visit if he/she fails to return for a scheduled study follow-up visit
Controls
 ► 2 through 23 months of age
 ► Cough <14 days or difficulty breathing
 ► Ability and willingness of child’s caregiver to provide informed consent and to be 
available for follow-up for the planned duration of the study, including accepting a home 
visit if he/she fails to return for a scheduled study follow-up visit
Exclusion criteria Cases
 ► Resolution of chest indrawing after bronchodilator challenge, if wheezing at screening 
examination
 ► Severe respiratory distress
 ► Arterial SpO2 <90% in room air, as assessed non-invasively by a pulse oximeter
 ► WHO IMCI general danger signs
 ► Stridor when calm
 ► Known or possible tuberculosis (history of a cough ≥14 days)
 ► Any medical or psychosocial condition or circumstance that, in the opinion of the 
investigators, would interfere with the conduct of the study or for which study 
participation might jeopardise the child’s health
 ► Living outside the study catchment area
Controls
 ► Axillary temperature ≥38°C
 ► Fast breathing for age
 ► Visible indrawing of the chest wall
 ► SpO2 <95% in room air, as assessed non-invasively by a pulse oximeter
 ► WHO IMCI general danger signs
 ► Stridor when calm
 ► Known or possible tuberculosis (history of a cough ≥14 days)
 ► Any medical or psychosocial condition or circumstance that, in the opinion of the 
investigators, would interfere with the conduct of the study or for which study 
participation might jeopardise the child’s health
 ► Living outside the study catchment area
IMCI, Integrated Management of Childhood Illnesses; RR, respiratory rate; SpO2, oxyhaemoglobin saturation.
interview (IDI) as well as direct observation while LUS is 
performed on their enrolled child.
study procedures
Study procedures are conducted according to the most 
recently approved version of the protocol (current 
version 1.9, 17 January 2018 (online supplementary 
appendix 1)). On Day 1, following screening and written 
informed consent, study staff perform the following 
procedures: assign participant identification number; 
collect information on location of residence, sociodemo-
graphic characteristics, environmental exposures, vacci-
nation history, concomitant medications and antibiotic 
use, current illness, pneumonia hospitalisation(s) and 
medical history; perform a physical examination; obtain 
CXR and LUS (within 8 hours after physical examina-
tion) and collect a respiratory specimen (cases only) and 
a blood sample.
Enrolled children are followed through hospital 
outcome as well as 14 days (in-person either in the 
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Table 2 Schedule of study visits and evaluations
Activity
Day 1: 
Screening and 
enrolment Day 2* Day 6* Day 14†
Day 30 
(phone)†
Unscheduled 
visit
Assess eligibility ✓
Obtain informed consent ✓
Assign participant identification number ✓
Collect/update locator information ✓ ✓ ✓ ✓ ✓
Collect sociodemographic information ✓
Collect information on environmental exposures ✓
Collect vaccination history ✓
Collect/update medical history ✓ ✓ ✓ ✓ ✓ ✓
Assess for general and respiratory danger signs ✓ ✓ ✓ ✓ ✓
Respondent assessment of current symptoms ✓ ✓ ✓ ✓ ✓ ✓
Clinician assessment of current symptoms ✓ ✓ ✓ ✓ ✓
Collect vital signs ✓ ✓ ✓ ✓ ✓
Perform targeted physical examination ✓ ✓ ✓ ✓ ✓
Collect/update concomitant medications/
antibiotics
✓ ✓ ✓ ✓ ✓ ✓
Collect/update hospitalisation log ✓ ✓ ✓ ✓ ✓
Perform chest X-ray ✓
Perform lung ultrasound ✓ ✓ ✓ ✓ ✓
Collect respiratory specimens ✓
Collect blood sample ✓
Refer to clinical care (as needed) ✓ ✓ ✓ ✓ ✓ ✓
Schedule next visit ✓ ✓ ✓ ✓
End of study questions ✓
*Window: +24 hours.
†Window: +/-72 hours days.
hospital, study clinic or the child’s home) and 30 
days (phone call) postenrolment (table 2). Caregivers 
are scheduled to bring their children for repeat LUS 
examinations and follow-up visits with the study staff 
on Days 2, 6 and 14. The protocol-specified window for 
completing each study visit is +24 hours (Days 2 and 6) 
and ±72 hours (Days 14 and 30). If a child presents to 
a study hospital during the period of his/her participa-
tion, an unscheduled visit may be performed. During 
follow-up and unscheduled visits, study staff obtain 
a LUS examination, review any changes in medical 
history and perform a physical examination. The Day 
30 phone call is intended to determine the child’s 
health status. Should the phone call detect any ongoing 
health problem, the child is referred to further care. All 
enrolled children receive local standard of care. Under 
no circumstances does the participation in the study 
interfere with or unnecessarily delay the management 
of sick children.
lung ultrasound and chest radiography examinations
LUS examinations are performed by trained non-phy-
sician healthcare personnel who received a 3-day stand-
ardised training course as well as 2 days of supervised 
practice prior to the initiation of study activities. During 
the LUS examination, longitudinal and oblique scans are 
obtained of the anterior, lateral and posterior sides of the 
child’s chest. Six areas are examined on each enrolled 
child, comprising the anterior, lateral and posterior areas 
of the lungs, further divided into the upper and lower 
halves. Study personnel begins by conducting a longitu-
dinal scan in each of the aforementioned areas. If any 
abnormality (eg, consolidation) is identified, an oblique 
scan is performed. The child is examined in his/her most 
comfortable position (eg, the caregiver’s arms).
To ensure quality and consistency of LUS collection and 
interpretation, on-site LUS training is performed prior to 
study initiation, video refresher trainings are performed 
as necessary during the study, and a LUS standard oper-
ating procedures (SOP) document provides an a priori 
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description of features typical to pneumonia diagnosis. A 
standardised LUS reporting form includes all chest areas 
examined as well as the patterns detected (ie, interstitial 
syndrome, consolidation, air bronchogram and pleural 
effusion; online supplementary appendix 2).8 The LUS 
interpretation targets the detection of typical subpleural 
lung consolidations with tissue-like or anechoic patterns 
and blurred, irregular margins. LUS is considered posi-
tive when consolidation and/or pleural showing features 
described in the LUS SOP is present on imaging. At 
least two independent physicians trained in LUS inter-
pret each examination. If discordant, a designated LUS 
interpretation expert acts as a tiebreaker. In addition to 
the aforementioned interpretation, the LUS operators at 
each site also interpret each examination in order to facil-
itate comparison between interpretations by physicians 
with extensive LUS training and those done by newly 
trained study personnel. To minimise bias, on-site LUS 
interpretation is performed after the fact (rather than 
in real-time) in batches, including examinations from at 
least four children. Results from the study LUS examina-
tions do not inform or impact the child’s clinical care.
CXR images are collected based on the current stan-
dard practice at each study site. The CXR interpretation 
panel investigates radiographic indicators of primary 
end-point pneumonia, in a process modelled after the 
WHO CXR standardised interpretation process.12–14 
Interpretation focuses on the presence of consolidation, 
infiltrates and/or effusion as well as additional findings 
(eg, atelectasis) to facilitate additional comparisons with 
LUS.8 At least two independent CXR-trained physicians 
interpret each CXR. If discordant, a designated CXR 
expert acts as tiebreaker. CXR collection and interpreta-
tion is further detailed in a CXR SOP.
sample collection and testing
For all cases, a blood sample is collected for haemo-
globin, malaria (Mozambique only), HIV screening 
(Mozambique only), bacterial invasive disease screening 
and biomarker assessment. For controls, a finger stick or 
blood sample for haemoglobin, malaria (Mozambique 
only), HIV screening (Mozambique only) is collected. 
Respiratory samples are collected from all cases. Naso-
pharyngeal swabs (Pakistan) or aspirates (Mozambique) 
are collected for respiratory viral and bacterial PCR 
using a commercial multiplex test. In Mozambique, naso-
pharyngeal swabs are also collected to evaluate carriage 
of bacterial pathogens.
Qualitative substudy
A mixed methods evaluation is conducted to assess the 
feasibility, usability and acceptability of LUS for diag-
nosing childhood pneumonia in a LRS. Semistructured 
IDIs are conducted among HCPs and administrators 
associated with the study. Direct observation and IDIs are 
conducted among caregivers of children enrolled in the 
overall study. During the IDIs, trained qualitative study 
staff introduce each question separately. If study staff 
do not get a satisfactory response (eg, the respondent 
does not understand the question, the respondent does 
not provide information that answers the question, the 
response lacks detail and so on), study staff repeat the 
question and probe for additional information, but do 
not prompt any responses. The IDIs are conducted in 
the language best understood by the caregiver (ie, Portu-
guese or Changana in Mozambique; Urdu or Sindhi 
in Pakistan). During the direct observation, study staff 
record how much time was spent explaining the LUS 
examination to the caregiver as well as any questions, 
comments or reactions by the caregiver.
sample size
The total sample size for this study is 270 children (100 
cases and 20 controls at the Mozambique site; 130 cases 
and 20 controls at the Pakistan site). This is a pilot study 
seeking to demonstrate feasibility of investigating LUS for 
pneumonia diagnosis and prognosis in a district facility 
setting. Its underlying purpose is to generate evidence 
to inform future full-scale studies. Thus, the sample size 
may not provide adequate power to answer all of the 
research questions laid out in this protocol. The sample 
size was selected to maximise the amount of information 
collected within the confines of the available resources. 
With the proposed 230 case participants, if an estimated 
30%–40% of enrolled children with chest indrawing 
is found to have pneumonia by CXR, we would have a 
sample of 70–90 case participants with radiologically 
confirmed pneumonia. We believe that this is sufficient 
to generate evidence and inform future studies regarding 
the use of LUS as a tool for pneumonia diagnosis and 
prognosis.
For the feasibility, usability and acceptability assessment, 
the total sample size is approximately 20 participants in 
each cohort (10 HCPs/administrators and 10 caregivers 
at each site). All study HCPs are invited to participate 
in the data collection procedures for this portion of the 
project; healthcare administrators may also be invited to 
participate.
data collection and quality assurance
Quantitative study data are collected by clinical study staff 
using designated source documents or paper-based case 
report forms which are then entered into a REDCap elec-
tronic database or via direct data entry into REDCap.15 
Qualitative study data are collected using paper-based 
forms and audio recordings which are subsequently tran-
scribed for analysis.
Clinical research data are maintained through a combi-
nation of secure electronic data management system 
and physical files with restricted access to ensure confi-
dentiality. Two distinct study databases are maintained 
separately by each study site: the primary study database 
with study visit data and a database with participating 
children’s personally identifiable information. To ensure 
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box 1 : Study endpoints
Primary endpoint
 ► Proportion of children with pneumonia suggested by LUS and/or 
CXR.
Secondary endpoints
 ► Proportion of children with pneumonia suggested by CXR but not 
LUS.
 ► Proportion of children with pneumonia suggested by LUS but not 
CXR.
 ► Proportion of children with no pneumonia identified.
 ► Aetiological diagnosis for each recruited child with samples 
collected.
 ► Proportion of children with a positive viral PCR.
 ► Difference in characteristic LUS imaging patterns between children 
with viral vs bacterial versus mixed pneumonia.
 ► Clinical and/or diagnostic biomarker outcomes.
 ► Patient status after 6 days of follow-up.
 ► Patient status after 14 days of follow-up.
 ► Patient status after 30 days of follow-up.
 ► Feasibility, usability and acceptability of LUS among HCPs.
 ► Acceptability of LUS among caregivers.
CXR, chest radiography; HCP, healthcare provider; LUS, lung ultrasound. 
accuracy and completeness, data are routinely reviewed 
by the sponsor through quality assurance reviews, audits 
and evaluation of the study safety and progress. Standard 
GCP is followed to ensure accurate, reliable and consis-
tent data collection.
data management
Primary data management activities, which include data 
entry and validation, data cleaning, database quality 
control and disaster recovery plans are undertaken 
at each study site and are overseen by the on-site data 
manager. Data review, oversight and preparation of final 
study database are performed by the sponsor in collabora-
tion with the study sites. Data are maintained in databases 
hosted at each study site. All data management activities 
are in compliance with International Council on Harmo-
nization (ICH) GCP E6, sponsor organisation and insti-
tutional requirements for the protection of children and 
confidentiality of personal and health information.
outcomes
We hypothesise (stated under the alternative) that for 
the diagnosis of CXR-confirmed pneumonia (radiolog-
ical endpoint pneumonia), the specificity of the WHO 
IMCI clinical assessment algorithm plus LUS is greater 
than the specificity of the WHO IMCI clinical assessment 
algorithm alone. The primary endpoint is the proportion 
of children with pneumonia suggested by LUS and/or 
CXR on enrolment. Secondary endpoints include the 
proportion of children with pneumonia suggested by 
CXR but not LUS or pneumonia suggested by LUS but 
not CXR. A full list of endpoints is presented in box 1. We 
also are conducting exploratory investigations regarding 
whether LUS may be able to help characterise and prior-
itise which children require hospitalisation or are at 
higher risk of progression of their pneumonia or acute 
process, whether LUS can identify characteristic imaging 
differences in viral versus bacterial versus mixed pneu-
monia and whether LUS is feasible, usable and accept-
able among HCPs and caregivers for diagnosing paedi-
atric pneumonia in a LRS.
statistical analyses
Sensitivity and specificity are calculated and McNemar’s test 
of paired data is used to compare discordance in results 
between LUS examination and the WHO IMCI clinical 
assessment algorithm. This is performed as a two-sided test 
with alpha=0.05. Interrater agreement for CXR and LUS is 
determined using kappa statistics.
Feasibility, usability and acceptability are assessed 
through qualitative data analysis of IDIs with HCPs and 
caregivers as well as direct observation with caregivers. 
The qualitative data are in narrative format and the 
results are descriptive. The transcripts are coded and 
analysed using a codebook and themes identified a priori, 
including opportunities and barriers for introduction 
of LUS, feasibility of implementing LUS and perceived 
value. Qualitative data analysis software (NVivo) is used 
to organise, code and analyse the qualitative data in an 
iterative process.
EthIcs And dIssEMInAtIon
Ethical approvals and consent
The study is conducted in accordance with the ICH GCP 
and the Declaration of Helsinki 2008. Written informed 
consent is obtained in the local language by trained study 
staff from all eligible children’s caregivers prior to enrol-
ment.
Possible risks
Caregivers may feel compelled to enrol in the study in 
order to receive care for their child within a research 
setting, which may be perceived as of a higher quality 
than the standard of care. In order to minimise the risk 
of coercion, hospital staff inform caregivers about the 
study and refer only those who are interested. During 
the informed consent process, study staff emphasise that 
the child will receive the required medical care whether 
enrolled in the study or not. Other potential risks to 
study participation may include those associated with 
collection of respiratory and blood specimens, CXR and 
LUS examinations and delayed medical management. 
In order to minimise the discomfort and risks associated 
with respiratory and blood specimen collection, study 
staff collecting specimens from children are trained in 
the appropriate procedures and supervised accordingly. 
Whenever possible, research blood draws are combined 
with clinical blood draws to minimise the amount of 
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needle sticks experienced by the child. Study staff imple-
menting CXR are trained in appropriate procedures 
and supervised accordingly with standard precautions 
in place to protect children from ionising radiation. To 
minimise the dose of ionising radiation, only one CXR 
is obtained during the study period; there are no repeat 
CXR assessments unless clinically indicated. Study staff 
implementing LUS examinations are trained in appro-
priate procedures and supervised accordingly with 
standard precautions in place. In order to minimise the 
possibility that participation in this study interferes with 
the medical management of hospitalised children, study 
staff are trained in integrating research procedures with 
clinical care. Urgent clinical care for acute medical issues 
is always prioritised above research procedures. Extreme 
care is taken to ensure that no necessary treatment is 
delayed to accommodate study procedures.
dissemination
We plan to disseminate study results in peer-reviewed 
journals and international conferences, targeting those 
involved in the clinical care of children in LRS as well 
as those who develop and advise on policies and guide-
lines in those settings. The trial is registered with  Clinical-
Trials. gov (registration number NCT03187067).
Efforts towards generalisable results
The study was carefully developed and pragmatically 
designed with inclusion and exclusion criteria to allow for 
the most generalisable results possible without putting chil-
dren with danger signs or severe respiratory distress at risk. 
Children with comorbidities such as malnutrition, anaemia, 
HIV and malaria are included in order to enrol a broad 
group of children. Enrolled cases have been diagnosed with 
chest indrawing pneumonia based on WHO IMCI clinical 
guidance, as is common in LRS where children are typically 
diagnosed based on clinical criteria alone.
Efforts towards rigorous protocol
Dedicated study staff trained in GCP, IMCI and study-spe-
cific procedures follow children enrolled in the trial to 
assure the protocol and SOPs are followed and data are 
accurately collected. Standardised training, supervision 
and oversight are undertaken to ensure quality, consist-
ency and harmonised trial procedures and implementa-
tion. Regular monitoring is provided by Save the Chil-
dren to assess compliance with human subjects and other 
research regulations and guidelines, adherence to the 
study protocol and procedures and quality and accuracy 
of data collected.
limitations and bias
Limitations to this study and potential sources of bias 
include the sampling strategy, harmonising the data 
between study sites, loss to follow-up and LUS and/or 
CXR interpretation bias. As noted above, given that the 
study is a pilot, the sample size may not provide adequate 
power to answer all of the proposed research questions. 
Because the study sites and the populations the hospital 
facilities serve are so different from each other, and the 
sample sizes of the enrolled children are relatively small 
at each study site, it may be difficult to harmonise the data 
between sites or data may simply represent the different 
underlying pneumonia epidemiologies. To mitigate 
this risk, we are applying the same enrolment criteria 
between study sites and are training study staff at both 
sites according to the same standardised protocols. We 
are also monitoring study staff performance with multiple 
quality control procedures and interim trainings. To 
minimise loss to follow-up, community sensitisation and 
outreach are performed and caregivers of enrolled chil-
dren are provided with clear follow-up instructions and 
reminders prior to the follow-up visits. Home visits take 
place among children who missed a follow-up visit. To 
eliminate LUS and/or CXR interpretation bias, trained 
panels of CXR and LUS experts interpret all images. The 
panels are blinded to each other’s interpretations, and 
discordant interpretations are adjudicated in a process 
modelled after the WHO CXR process.12 LUS and CXR 
interpretations are based on a priori guidance set forth in 
the LUS and CXR SOPs.
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